Tangible Impact
Our support enabled the successful listing of our client’s novel IBS product on the NHS Drug Tariff, securing access to NHS reimbursement and expanding market potential. Our health economic evaluation provided the critical evidence needed to demonstrate the product’s cost-effectiveness, ensuring a compelling submission. The client’s application was approved, helping patients with IBS gain access to an innovative intervention while driving commercial success.
“Thank you for your invaluable help in allowing us to achieve a listing on the NHS Drug Tariff! We are very pleased, and the Health Economic model for IBS helped enormously.” – Research Director
Assessing the Challenge
Our client sought NHS Drug Tariff listing for their innovative IBS treatment, requiring a robust health economic evaluation to demonstrate cost-effectiveness. With a recently completed randomised controlled trial (RCT) available, the challenge was to translate clinical data into compelling economic evidence aligned with NHS decision-making criteria.
Tailored Approach
We conducted a comprehensive review of the RCT data, focusing on disease progression and quality-adjusted life-years (QALYs). Leveraging these insights, we developed a Markov Model to simulate the long-term cost-effectiveness of the product. To ensure adaptability, we incorporated future potential benefits, such as reduced consultations and lower concomitant medication use. Additionally, we provided strategic support in refining the submission dossier to NHS Prescription Services, ensuring a strong and well-positioned application.
